New radiation treatment significantly increases survival rate

October 16, 2012

A novel drug that mimics a naturally occurring molecule found in coffee and blueberries has been developed to treat radiation exposure. Charles R. Yates, Pharm.D., Ph.D., and colleagues Duane Miller, Ph.D., and Waleed Gaber, Ph.D., from the University of Tennessee Health Science Center and Baylor College of Medicine, show that application of this drug, starting 24 hours after radiation exposure, increases survival in animal models by three-fold compared to placebo.

Their work, which is funded through an NIH grant from the National Institute for Allergy and Infectious Diseases, is being presented at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Chicago, Ill., Oct. 14 – 18.

"Development of drugs for individuals who are exposed to high- in a has been a priority since the 9/11 terrorist attacks," said Yates. "The ultimate goal is wide dissemination of non-invasive treatments after 24 hours of a mass casualty."

The high risk of vomiting after proves problematic for oral treatments, the most common non-invasive delivery method. Injectable medication is often proposed as the next line of defense, which comes with its own challenges. For example, training is often required for injections. To combat this problem, Yates and his team designed a new delivery system that can be applied directly to the skin, similar to an adhesive bandage.

"We are extremely proud to have exclusive rights to this exciting technology," said W. Shannon McCool, D.Ph., president & CEO of RxBio, the entity that has licensed the technology from the University of Tennessee Research Foundation.

This drug is also highly effective in models where radiation exposure is combined with skin wounds – a likely scenario in which people are exposed to shrapnel from dirty bombs or associated burn wounds.

Explore further: Innovative transdermal patch for delivery of HIV medicine featured at AAPS Annual Meeting

Related Stories

Innovative transdermal patch for delivery of HIV medicine featured at AAPS Annual Meeting

October 25, 2011
An innovative delivery method for human immunodeficiency virus (HIV) medications has been developed through use of a transdermal patch, the first of its kind to treat HIV. This research is being presented at the 2011 American ...

Novel biomarkers reveal evidence of radiation exposure

May 22, 2012
Researchers at the Medical College of Wisconsin have identified novel biomarkers that could be used to confirm exposure to damaging radiation in large groups of people potentially exposed to unknown and variable doses for ...

Researchers successfully treat previously lethal doses of radiation

January 5, 2012
Multiple scenarios exist where warfighters may be exposed to high levels of radiation. Countermeasures against possible high doses of radiation are an ongoing high priority for Department of Defense research and development ...

Recommended for you

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...

Metabolism can be used to subtype hepatoblastoma tumors

September 18, 2017
Looking at cell metabolism instead of histology, EPFL scientists have identified new biomarkers that could help more accurately classify the two main subtypes of hepatoblastoma, a children liver cancer.

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Scientists find bacteria in pancreatic tumors that metabolize a common drug

September 15, 2017
To the reasons that chemotherapy sometimes does not work, we can now add one more: bacteria. In a study published today in Science, researchers describe findings that certain bacteria can be found inside human pancreatic ...

New technologies combined to identify specific DNA defect underlying a type of cancer

September 15, 2017
(Medical Xpress)—A team of researchers from the Netherlands and the U.K. has developed a technique for studying inherited types of cancers using two relatively new technologies—organoid development and CRISPR/Cas9. In ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.